U.S. markets close in 53 minutes
  • S&P 500

    4,076.28
    -75.82 (-1.83%)
     
  • Dow 30

    33,720.00
    -549.16 (-1.60%)
     
  • Nasdaq

    13,058.69
    -330.74 (-2.47%)
     
  • Russell 2000

    2,164.56
    -42.43 (-1.92%)
     
  • Crude Oil

    66.02
    +0.74 (+1.13%)
     
  • Gold

    1,821.40
    -14.70 (-0.80%)
     
  • Silver

    27.64
    -0.02 (-0.06%)
     
  • EUR/USD

    1.2085
    -0.0068 (-0.56%)
     
  • 10-Yr Bond

    1.6930
    +0.0690 (+4.25%)
     
  • GBP/USD

    1.4060
    -0.0084 (-0.59%)
     
  • USD/JPY

    109.5590
    +0.9390 (+0.86%)
     
  • BTC-USD

    53,902.34
    -2,748.45 (-4.85%)
     
  • CMC Crypto 200

    1,448.29
    -115.54 (-7.39%)
     
  • FTSE 100

    7,004.63
    +56.64 (+0.82%)
     
  • Nikkei 225

    28,147.51
    -461.08 (-1.61%)
     

EMA starts review of GSK's monoclonal antibody to treat COVID-19 patients

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

April 15 (Reuters) - The European Medicines Agency said on Thursday it is reviewing available data on the use of GlaxoSmithKline's monoclonal antibody to treat COVID-19 patients.

The agency said its review of VIR-7831 will include data from a study comparing its effect with that of a placebo in patients with mild to moderate COVID-19 who were at high risk of progressing to a more severe condition. (https://bit.ly/3n0spGx)

A more comprehensive rolling review is expected to start at a later time, the agency said. (Reporting by Vishwadha Chander in Bengaluru; Editing by Bernard Orr)